Abstract
Dupilumab, a fully human mAb, blocks the shared receptor component for interleukin-4/interleukin-13. In the 3-part, phase 3 LIBERTY-EoE-TREET study (NCT03633617), Part A/C demonstrated efficacy/safety of dupilumab 300mg weekly (qw) in adolescent/adult (≥12 years) EoE patients for 24 weeks, which was sustained up to Week 52. Part B assessed efficacy/safety of dupilumab 300mg qw or every 2 weeks vs placebo up to 24 weeks in a larger sample size of adolescents/adults with EoE.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
